Epetraborole for Mycobacterium abscessus lung infection
Part of Infections clinical trials.
This study tests an investigational medication called epetraborole for people with a chronic lung infection caused by Mycobacterium abscessus bacteria. You may be able to join if your infection is stable enough to delay standard treatment and you have symptoms like cough, fatigue, or weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a positive sputum test for Mycobacterium abscessus in the past 6 months, and another positive test at screening.
- You have at least 2 of these symptoms: chest pain, chronic cough, coughing up blood, fatigue, fever, mucus production, night sweats, poor appetite, shortness of breath, or unintentional weight loss.
- You have a recent chest CT scan showing lung changes related to Mycobacterium abscessus.
- You don't need to start standard antibiotics for this infection in the next 6 months, and you agree to take part in a placebo-controlled study.
- You are willing to use effective birth control if applicable, and you don't have other serious lung conditions like cystic fibrosis or active cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of antibiotics (Arm D) against the standard treatment for people with a difficult-to-treat lung infection called Mycobacterium abscessus. It is for adults and teens aged 12 and older, including those with cystic fibrosis.
This study tests whether a new antibiotic, Contezolid, can quickly reduce the amount of Mycobacterium abscessus in your lungs. It may be a treatment option if you have had a positive sputum test in the past 6 months.
This trial tests whether omadacycline (an antibiotic) can safely and effectively treat a rare lung infection caused by Mycobacterium abscessus bacteria. If you have this infection, this study may help doctors understand if this antibiotic works better than current treatments.
This is a special program for one patient with a lung infection from Mycobacterium abscessus. The trial uses a treatment with bacteriophages, which are viruses that attack specific bacteria.
This study follows people with a newly diagnosed MAC lung infection (a specific type of mycobacterial disease) and tests how they do on the standard three-drug treatment plan. It may help researchers better understand outcomes and safety for this condition.
This study tests if adding traditional Chinese medicine to standard treatment helps people with a lung infection called Mycobacterium abscessus. It may improve recovery and reduce side effects.
Hear when a new Mycobacterium Abscessus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.